SCHEMBL6417102

SCHEMBL6417102

O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCOCCOCCOCCOCCOCCn1cc2c2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 18/20 1.00
PRKCG P05129 15/20 1.00
PRKCB P05771 15/20 1.00
PRKCA P17252 14/20 1.00
CDK1 P06493 3/20 1.00
CDK2 P24941 2/20 1.00
PRKCQ Q04759 2/20 1.00
PRKCE Q02156 6/20 0.85
PRKCD Q05655 5/20 0.81
CCNB2 O95067 1/20 0.80
PDGFRB P09619 1/20 0.80
CCNB1 P14635 1/20 0.80
PDGFRA P16234 1/20 0.80
PRKACA P17612 1/20 0.80
PRKACG P22612 1/20 0.80
PRKACB P22694 1/20 0.80
KDR P35968 1/20 0.80
CAMK2B Q13554 1/20 0.80
CAMK2G Q13555 1/20 0.80
CAMK2D Q13557 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4345338 1.00 GSK3B (1.00) GSK3BPRKCGPRKCBPRKCACDK1
Indolylylmaleimide 2 SCHEMBL4341971 1.00 GSK3B (1.00) GSK3BPRKCGPRKCBPRKCACDK1
SCHEMBL4342534 1.00 GSK3B (1.00) GSK3BPRKCGPRKCBPRKCACDK1
SCHEMBL22765525 0.99 GSK3B (0.97) GSK3BPRKCGPRKCBPRKCACDK1
SCHEMBL25778145 0.95 GSK3B (0.90) GSK3BPRKCGPRKCBPRKCACDK1
SCHEMBL4344559 0.92 GSK3B (1.00) GSK3BPRKCGPRKCBPRKCACDK1
SCHEMBL4336077 0.90 GSK3B (1.00) GSK3BPRKCGPRKCBPRKCACDK1
SCHEMBL4344077 0.89 GSK3B (1.00) GSK3BPRKCGPRKCBPRKCACDK1
SCHEMBL4351003 0.89 PRKCG (1.00) GSK3BPRKCGPRKCBPRKCACDK1
SCHEMBL4346022 0.89 GSK3B (1.00) GSK3BPRKCGPRKCBPRKCACDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2664669-B1 TREATMENT OF PLURIPOTENT CELLS JANSSEN BIOTECH INC (US) 2017-12-27 EP disclosed
EP-2664669-A1 Treatment of pluripotent cells Janssen Biotech, Inc. (US) 2013-11-20 EP disclosed
EP-1345946-B1 MACROHETEROCYLIC COMPOUNDS USEFUL AS KINASE INHIBITORS ORTHO MCNEIL PHARM INC (US) 2005-08-10 EP disclosed